Egfr+ but getting immunotherepy?

[Kelvin4426]

Hi guys so my mom is egfr+ but they are putting her on immunotherepy for a year after her chemo and radiation which she finished on Monday. People say that immuno isn't good with people rhat are egfr+ so I wanted to see if anyone else has this plan. We life in canada so it's a little different when looking for a 2nd opinion

[LilyMir]

Did you ask her doctor this question Kelvin?   Maybe take some online resources of what worries you ( immuno supposedly being bad for EGFR) and ask for an explanation?

I have no clue. I am EGFR but they will put me on Tagrisso for 3 years after adjuvant chemo. No one mentioned immuno. However, I had resection surgery so different than your mom’s situation. Second opinion is always good. 

[Judy M2]

I said this in another thread, but a second opinion with an EGFR expert is in order. In the past, the Canadian health system approved Tagrisso as adjuvant therapy provided the T790M mutation was present. All that evidently changed in 2018, when Tag was approved as first-line treatment with no T790M mutation required (see link below). I still see comments in Facebook groups where non-US folks must have T790M to qualify for Tag in their country. 

I'm sure that the International Lung Cancer Survivorship Conference will discuss immunotherapy for EGFR+ lung cancer, it's a question that is continually asked in EGFR forums. 

https://www.astrazeneca.ca/en/media/press-releases/2018/health-canada-approves-tagrisso---osimertinib--as-first-line-tre.html#

[Judy M2]

The question of immunotherapy for EGFR was answered in today's EGFR breakout session of LUNGevity's International Lung Cancer Survivorship Conference. Immunotherapy is not recommended for EGFR patients. The patient will not receive any benefit from it. I strongly urge Kelvin's mom to get a second opinion. 

[Kelvin4426]

15 minutes ago, Judy M2 said:

The question of immunotherapy for EGFR was answered in today's EGFR breakout session of LUNGevity's International Lung Cancer Survivorship Conference. Immunotherapy is not recommended for EGFR patients. The patient will not receive any benefit from it. I strongly urge Kelvin's mom to get a second opinion. 

Hey thanks for this information I have told my mom to ask her doctor why they plan on going on immuno instead of target she meets with her jn 2 weeks. Is there a way I can watch this session

[Judy M2]

I think there may be a recording available in a few days, so keep checking the home page. 

[Judy M2]

If you register here, the recordings will be available for a while:

https://www.lungevity.org/blogs/ILCSC2022

[Karen_L]

A study called the Pacific study established a new standard of care for certain stages or configurations of lung cancer. It calls for simultaneous chemo and radiation (chemorads) followed by a year of durvalumab, an immunologic agent.

Dr. David Carbone spoke about the Pacific study in his keynote talk for the conference that @Judy M2has mentioned. Carbone called the Pacific study “a landmark study that has changed practice.”   He said a five-year survival update showed that patients who completed the treatment had major, clinically and statistically durable improvement in life expectancy. Carbone did not mention specific mutations, but the purpose of his keynote was to give an overview of what’s been happening, not get into the nitty gritty of mutations and treatment plans. 

I can’t recall all the details of your mom’s situation, but it may be that her treatment plan is based on the conditions that best match the protocols of the Pacific—or some other— study. 

I, too, heard the EGFR specialist say immunology and EGFR aren’t a match, but I’m unsure whether she meant any immunology at any point in treatment, or whether adjuvant therapy (after an initial treatment) was different. 

I encourage you to call to ask about the doctor’s thinking on this, before your mom’s next appointment. It’s never comfortable, but you just keep asking until you get the insight you need. 

[Kelvin4426]

On 7/18/2022 at 11:04 PM, Karen_L said:

A study called the Pacific study established a new standard of care for certain stages or configurations of lung cancer. It calls for simultaneous chemo and radiation (chemorads) followed by a year of durvalumab, an immunologic agent.

Dr. David Carbone spoke about the Pacific study in his keynote talk for the conference that @Judy M2has mentioned. Carbone called the Pacific study “a landmark study that has changed practice.”   He said a five-year survival update showed that patients who completed the treatment had major, clinically and statistically durable improvement in life expectancy. Carbone did not mention specific mutations, but the purpose of his keynote was to give an overview of what’s been happening, not get into the nitty gritty of mutations and treatment plans. 

I can’t recall all the details of your mom’s situation, but it may be that her treatment plan is based on the conditions that best match the protocols of the Pacific—or some other— study. 

I, too, heard the EGFR specialist say immunology and EGFR aren’t a match, but I’m unsure whether she meant any immunology at any point in treatment, or whether adjuvant therapy (after an initial treatment) was different. 

I encourage you to call to ask about the doctor’s thinking on this, before your mom’s next appointment. It’s never comfortable, but you just keep asking until you get the insight you need. 

Hi thanks for the reply. From the looks of it the treatment sounds similar to my mom's. She did her 2 cycles of chemo and finished her radiation and was told she will start immunotherepy for a year. My mom has an appt with her oncologist this Tuesday so she will ask questions I'll keep updated